Vinod E. Nambudiri, MD, MBA, MPH, is affiliated with Brigham and Women's Hospital and specializes in Dermatology and Internal Medicine.

Vinod Nambudiri, MD, MBA, MPH, of Brigham and Women’s Hospital spoke with 

’s editorial team on-site at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, Colorado, and in a segment of the 

 spoke about advancing dermatologic education in terms of diversity.

During this interview, included as a segment of the podcast, Nambudiri spoke about the progress made in improving clinical education image diversity and remaining gaps in addressing conditions that disproportionately affect individuals with skin of color. Specifically, he spoke about the AAD Clinical Image Collection, launched in 2025, and its impact on these issues.

In the following Q&A summary, Nambudiri’s responses to inquiries by 

 reflected the increasing momentum in the dermatology space regarding both inclusivity and equity:

 We are on-site, live at the AAD 2026 Meeting in Denver, Colorado, here with Dr. Vinod Nambudiri, who is going to talk to us a little bit about some different topics today. Would you first describe a little bit about your background?

Thanks so much for having me here…I am a medical dermatologist based out of Brigham and Women's Hospital in Boston, and my clinical work spans medical dermatology as well as the care of patients in oncodermatology or cutaneous oncology. Outside of my clinical work, I also spend a lot of time thinking about medical education, overseeing our residency program for trainees in the Harvard combined dermatology residency system, and I do some administrative work in our hospital related to clinician well-being, as well as thinking about some of the factors that are at play there.

 We wanted to talk to you today about the AAD Clinical Image Collection, which is a topic we've discussed a bit before. Could you first go into a bit about the impetus for developing this collection and what kinds of gaps it was designed to fill?

Sure. The image collection is a several-year process in the making, and the AAD has historically been a wonderful leader in the space of education in dermatology, often viewed as sort of the gold standard of educational materials and products and resources for the training of dermatologists. [This is] both during their clinical training phase, but also lifelong. They also do a lot of work related to patient education materials and such. One of the gaps that was noted, not only in the AAD’s scope of medical education, but really in many forms of resources that exist and particularly dermatology textbooks and other kind of reference materials for educating dermatologists about skin disease, is that there was a real lack of diversity of representation within the teaching materials, within these clinical images.

In particular, one of the things that was lacking was a spectrum of skin tones or skin colors in which various clinical conditions were presented. And in fact, in some cases where skin tones or skin colors were overrepresented disproportionately, that could lead to potential downstream consequences for dermatologists or other physicians having gaps in their knowledge about how diseases present in a variety of skin tones and skin colors. So, with that impetus of really wanting to meet a need for the dermatologist's membership, that was recognized by dermatologists themselves. The Clinical Image Collection was set up by the AAD in order to help address that gap.

 How has the collection sort of grown since its launch in 2025?

We got things off the ground officially in January 2025 with sort of a soft launch, a little bit of buzz. Then by March of 2025, at the AAD in Orlando, at that time, we had our first official welcoming and launch event at that meeting, which was really fantastic. We have a work group of about 8 or 9 members that are involved. All of them are AAD members who are actively engaged in curating this collection. We're very fortunate to be partnering with Skin of Color Society, and they have representation in our work group as well to have inputs from a variety of dermatologists who are passionate about this work.

Since that time, we have grown tremendously. We started with a few dozen images in the collection. As of February of this year, just over a year after our launch, we have over 1800 images in our collection, over 3000 members who have accessed or created an account to access the AAD clinical image collection, and over 65,000 views of the images. So I think we've had tremendous growth in that one year. It's definitely been something that generated a fair amount of buzz within our specialty, and was really celebrated by the leadership of the AAD, which I think has helped champion it to a variety of our members, and has allowed it to grow through the contributions of individual AAD members themselves.

 What kind of images are included in the collection, and how can clinicians in dermatology use the collection?

 Fantastic question. We really are wide open in terms of diseases and morphologies. We want this to be a representative collection, meaning everything is fair game when an AAD member goes to submit a clinical photo or clinical image. They tag it to a specific diagnosis, and those diagnoses represent the full spectrum of dermatology. So we have pictures of inflammatory diseases like atopic dermatitis, psoriasis, hydratinitis, and alopecia, the spectrum of inflammatory diseases. We have pictures of skin malignancies, including melanomas, squamous cell carcinoma, basal cell carcinoma, and cutaneous lymphomas. We have pictures that represent chronic conditions in various states.

So, pre-treatment or post-treatment, we have images of infectious diseases of the skin, and so I'd say it really, truly represents a wide spectrum of disease and continues to grow. So those are a handful of the categories of diagnosis that are there. We also have every image in the collection tagged, not only by its diagnosis, but by its skin tone that it represents, essentially light, medium, or dark. That allows for a user to search through it for individual images based on those tagged diagnoses or skin tone, or even the relative age of the patient. Is this a pediatric patient? Is this an adult patient? So, we really hope to make this a usable, user-friendly platform or site for our members to be able to take advantage of.

We also wanted to ask who can use the collection?

 It's open to any and all AAD members. We hope that they are able to take those images and use them to educate, and really quite broadly across the scope of medicine and medical education. Whether that's their own trainees in the field of dermatology, whether it's medical students who are going into any different discipline, whether it is peers and colleagues in other specialties of medicine, maybe an emergency room physician who is diagnosing a rash, maybe an allergist that is diagnosing a drug reaction in the skin, any of these groups of individuals could really stand to benefit from additional clinical imaging that's been vetted and curated by dermatologists to represent disease across a spectrum of skin tones. So that's really the use case.

I know of colleagues who have used images from the collection in talks at the AAD. And that's a great kind of full circle moment here, of something that, like the membership identified that they needed, we created, pushed out to them, and then has now been used to, like, educate more members. I think that's sort of like a really nice, full-circle moment, and we're anticipating more of those as time comes.

What is your hope for expansion of the collection?

Well, some really exciting news on that front. We are, as I've mentioned, dependent upon members to really engage with us and donate images or upload images to the collection, and we've had really great uptake, hundreds of members who have thus far contributed. But we're very excited that we can announce or that we've been the recipient of a few large donations each, well over 1000 images that will allow us over the course of the next year, as we vet and process and digitize and upload all of these to have our goal over 10,000 of these uploaded into the collection as soon as we're able to so I think that really speaks to this exponential growth that we're able to achieve due to the support of our membership.

The quotes used in this Q&A summary were edited for the purposes of clarity.

Nambudiri V. Skin of Color Savvy: Updates on the AAD Clinical Image Collection, With Vinod Nambudiri, MD, MBA, MPH. HCPLive. April 14, 2026. Accessed April 29, 2026. 

https://www.hcplive.com/view/skin-of-color-savvy-updates-aad-clinical-image-collection-vinod-nambudiri-md-mba-mph

Nambudiri V. How the AAD Clinical Image Collection Can Help Dermatologists, With Vinod Nambudiri, MD, MBA, MPH. HCPLive. April 16, 2026. Accessed April 29, 2026. 

https://www.hcplive.com/view/how-aad-clinical-image-collection-can-help-dermatologists-vinod-nambudiri-md-mba-mph

Articles

Vinod Nambudiri outlines efforts to improve dermatologic diagnostic accuracy and equity through the AAD Clinical Image Collection, created to address underrepresentation of darker skin tones in teaching materials. Launched in early 2025 and curated by an 8–9 member workgroup with Skin of Color Society partnership, the resource expanded from dozens to >1,800 images, >3,000 users, and >65,000 views within a year. Images span inflammatory, infectious, and neoplastic conditions, tagged by diagnosis, skin tone, age, and treatment state for searchable educational use.

This Q&A interview with Nambudiri covers the AAD Clinical Image Collection, launched in January 2025 to address diversity in dermatology education.



Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Q&A: How Dermatologists Can Utilize the AAD Clinical Image Collection, With Vinod Nambudiri, MD, MBA, MPH

Tatyana Kushner, MD, is an associate professor of medicine in the division of gastroenterology and hepatology at Weill Cornell Medicine.

Brelovitug Offers New Hope for Hepatitis D Treatment

As interest grows in therapeutic development for hepatitis D virus (HDV), understanding how clinical trial endpoints translate into meaningful patient benefit remains a critical focus for clinicians. Unlike more common liver diseases, HDV trials rely on well-defined surrogate markers that reflect both viral activity and liver health. These endpoints are not only essential for regulatory evaluation but also serve as key indicators of whether emerging therapies may alter the natural history of this aggressive disease.

In the phase 2b portion of the AZURE-1 study, investigational agent brelovitug demonstrated success against the US Food and Drug Administration (FDA)-specified composite primary endpoint, which includes at least a 2-log reduction in HDV RNA alongside normalization of alanine aminotransferase (ALT). In an interview with HCPLive, Tatyana Kushner, MD, emphasized that while this endpoint is considered a surrogate, it is strongly associated with clinically meaningful outcomes.

Check out part 1 of the interview with Kushner 

“We care about both,” she explained, pointing to the importance of reducing viral replication while simultaneously improving liver inflammation, as reflected by ALT levels.

In the study, brelovitug met the primary endpoint across multiple dosing arms, reinforcing its potential as a therapeutic option in a space where treatment choices remain extremely limited. Beyond the binary endpoint achievement, Kushner highlighted the continuous decline in HDV RNA over time among treated patients, suggesting that longer treatment durations could yield even greater response rates, a question that ongoing and future analyses will aim to address.

For both clinicians and patients, these improvements are more than abstract metrics. Virologic decline offers tangible reassurance that the virus is being suppressed, while normalization of ALT provides evidence of reduced liver inflammation. Kushner noted that patients are often highly attuned to these laboratory values, particularly after years of limited treatment options and persistently abnormal results. The hope is that these biochemical improvements will ultimately translate into downstream clinical benefits, including reduced fibrosis progression and lower risk of liver-related complications.

According to phase 2b findings, brelovitug was generally well tolerated, with the most commonly reported adverse events being injection site reactions, an expected finding for a subcutaneous therapy. Of note, the flu-like symptoms frequently associated with pegylated interferon were largely absent. This distinction could represent a meaningful advantage in real-world practice, where tolerability often limits treatment uptake and persistence.

The study population itself further underscores the significance of these findings. Kushner pointed out that AZURE-1 included patients with a broad range of disease severity, without strict limitations on baseline ALT levels or fibrosis stage. As a result, some participants had advanced liver disease, including compensated cirrhosis, and potentially significant portal hypertension. Despite this higher-risk population, brelovitug demonstrated both efficacy and tolerability, strengthening confidence in its potential applicability across a wide spectrum of patients.

Editors’ Note: Kushner reports relevant disclosures with Gilead, Abbvie, GSK, Ipsen, Mirum, and Madrigal.

US Centers for Disease Control and Prevention. Hepatitis D Basics. April 24, 2024. Accessed April 29, 2026. 

https://www.cdc.gov/hepatitis-d/about/index.html

Ghany MG, Pan CQ, Lok AS, et al. AASLD ISDA Practice Guideline on treatment of chronic hepatitis B. 

. Published online November 4, 2025. doi:10.1097/HEP.0000000000001549

Mirum Pharmaceuticals. Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 2b Portion of the AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus. April 27, 2026. Accessed April 29, 2026. 

https://ir.mirumpharma.com/news/news-details/2026/Mirum-Pharmaceuticals-Announces-Primary-Endpoint-Met-in-Phase-2b-Portion-of-the-AZURE-1-Study-of-Brelovitug-in-Chronic-Hepatitis-Delta-Virus/default.aspx

Videos

Brelovitug achieved the FDA-specified primary endpoint for HDV RNA reduction and normalization of ALT in a phase 2b trial.

Hepatology

Hepatitis C

Hepatitis C page, resources on the topics of medical news and expert insight into HCV can be found. Content includes articles, interviews, videos, podcasts, and breaking news on hepatitis C virus research, treatment, and drug development.

AZURE-1: Brelovitug Meets Key Endpoints in Hepatitis D, With Tatyana Kushner, MD

Julie Silverstein, MD, is the medical director of the pituitary center and of the clinical trials unit and professor of medicine and neurological surgery at WashU Medicine.

Relacorilant Reduces HbA1c in Cushing’s Despite GLP-1 Treatment, With Julie Silverstein, MD

Relacorilant reduced hemoglobin A1c (HbA1c) by nearly 1% in patients with 

 and hyperglycemia despite ongoing GLP-1 treatment, according to a secondary analysis of the GRACE phase 3 clinical trial.

American Association of Clinical Endocrinology (AACE) Annual Meeting 2026

 in Las Vegas, Nevada, by Julie Silverstein, MD, medical director of the pituitary center and of the clinical trials unit and professor of medicine and neurological surgery at WashU Medicine. In an interview with 

, Silverstein discusses the complex pathway between excess cortisol and a plethora of long-term health detriments.

“There are multiple parts at play,” Silverstein told 

. “When you have excess cortisol, you have increased glyconeogenesis in the liver. This increased fasting glucose impairs interferon signaling, including GLP-1 receptor signaling. It leads to increased insulin resistance in the adipose tissue, decreasing uptake of glucose in the skeletal tissue.”

The original GRACE trial was a phase 3, double-blind, placebo-controlled, randomized-withdrawal study assessing the safety, efficacy, and pharmacokinetics of relacorilant in patients with endogenous Cushing syndrome and concurrent type 2 diabetes mellitus/impaired glucose intolerance (DM/IGT) and/or uncontrolled hypertension. Patients were excluded from the trial if they had non-endogenous hypercortisolism, uncontrolled, clinically significant hypo- or hyperthyroidism, poorly controlled hypertension, severe renal insufficiency, or poorly controlled diabetes mellitus.

In the open-label phase, patients were assigned to receive relacorilant in 100 mg capsules, increased sequentially to a maximum dose of 400 mg once daily; after 22 weeks, patients were then evaluated for inclusion in the randomized-withdrawal phase based on predefined hyperglycemia and hypertension response criteria. Eligible patients were then randomly assigned in a 1:1 ratio to either relacorilant or placebo for 12 weeks.

GRACE ultimately achieved its primary endpoint, as substantially more participants who were switched to placebo lost hypertension control versus those who stayed on relacorilant (odds ratio [OR], 0.17; 

 = 0.02). However, a subgroup of participants had hyperglycemia despite using GLP-1s or dual GIP/GLP-1s.

To that end, Silverstein and colleagues undertook this analysis to examine this subgroup. Patients taking GLP-1s or GIP/GLP-1s prior to and for ≥80% of the open-label phase were included in the trial. The team utilized a mixed model for repeated measures to analyze least squares mean change from baseline to the open-label period week 22 in HbA1c, weight, waist circumference, and body composition.

A total of 152 patients were enrolled in the open-label phase; of these, 28 had hyperglycemia despite using GLP-1s or GIP/GLP-1s. Baseline mean HbA1c, weight, and waist circumference were 8.5%, 108.4 kg, and 124.8 cm, respectively. Investigators recorded baseline tissue lean mass percentage at 53.2%. Among this group, relacorilant treatment led to substantial reductions in HbA1c from baseline (-0.9%; 95% CI, -1.6 to -0.3; 

“There are glucose receptor modulators being studied in other diseases,” Silverstein said. “Relacorilant, in fact, in combination with a chemotherapeutic agent, is FDA approved for the treatment of platinum resistant ovarian cancer; there’s a glucose receptor modulator being investigated for patients with MASH; I think there’s also a modulator being studied in patients with ALS. There seems to be lots of different areas where these could be used clinically.”

Editors’ Note: Silverstein reports disclosures with Xeris, Chiesi, Camurus, Ascendis Pharma, Bayer, Recordati, and others.

Silverstein J, Dobri G, Elenkova A, et al. Relacorilant Treatment Improves Glycemic Control Among Individuals With Cushing Syndrome (Endogenous Hypercortisolism) and Hyperglycemia on Glucagon-Like Peptide-1 Receptor Agonists: Insights From a Phase 3 Study. Abstract presented at the American Association of Clinical Endocrinology Annual Meeting 2026, Las Vegas, NV. April 22-24, 2026.

Corcept Therapeutics. A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome (GRACE). ClinicalTrials.gov Identifier: NCT03697109. Updated July 16, 2025. Accessed April 29, 2026. 

https://clinicaltrials.gov/study/NCT03697109

Silverstein addresses a secondary analysis of the GRACE trial, highlighting relacorilant’s efficacy in reducing cortisol in patients taking GLP-1 RAs.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Low-Dose Radiation Therapy Gains Traction in US, With Hirsch Sudhir Matani, MD

Low-dose radiation therapy (LDRT) is emerging in US clinical practice as a noninvasive option for chronic musculoskeletal pain, particularly osteoarthritis and other degenerative or inflammatory conditions, with early clinical experience suggesting meaningful pain reduction and a favorable safety profile in appropriately selected patients.

 Hirsch Sudhir Matani, MD, radiation oncologist at Keck Medicine of USC, described LDRT as a long-established treatment in Europe that is beginning to gain renewed interest in the United States as awareness increases and supporting clinical data continue to accumulate. Adoption in the United States has historically been limited, reflecting differences in training and referral patterns.

“I guess the main reason why it hasn't been adopted as broadly [in the US] is the landscape of healthcare and the differences that are our systems compared with Europe,” Matani said.

Matani noted that increasing engagement from professional societies, including the American Society for Radiation Oncology (ASTRO), has contributed to renewed discussion regarding the role of radiation therapy in nonmalignant disease states.¹ As clinicians reassess nonpharmacologic options for chronic pain, LDRT is being reconsidered within multidisciplinary care models.

A key distinction between LDRT and oncologic radiation therapy lies in dose and biologic effect. Cancer treatment commonly involves cumulative doses in the range of approximately 50 to 80 Gy, depending on tumor type and treatment intent. In contrast, LDRT for benign disease typically uses low single-digit gray doses, often around 3 Gy, delivered in limited fractions. At these lower doses, radiation is thought to exert anti-inflammatory rather than cytotoxic effects.

Clinically, LDRT is most commonly applied in conditions such as osteoarthritis, plantar fasciitis, Dupuytren contracture, and Ledderhose disease. Patient selection generally focuses on individuals with persistent symptoms despite conservative management, often defined as ≥ 6 months of ongoing pain that has not responded adequately to nonsteroidal anti-inflammatory drugs, physical therapy, or intra-articular injections.

Across published European experience and institutional reports, approximately 60% to 80% of patients experience some degree of pain improvement following LDRT, ranging from partial relief to more substantial functional improvement.2 Research has shown that pain relief has lasted up to 2 years.3 Available evidence suggests a low incidence of adverse effects with low-dose LDRT.

Standard care for osteoarthritis and related conditions typically includes pharmacologic therapies such as NSAIDs or corticosteroids, physical therapy, and, when appropriate, surgical referral.

“We generally treat patients [with LDRT) who are either not surgical candidates or don't want surgery, and they've tried some other interventions that haven't really worked,” Matani said. “I could see that evolving over as we in the US…get more used to using low-dose radiation and as primary care providers and other doctors see that it works with limited side effects.”

Reported disclosures for Matani include Icotec Medical Inc. and GlaxoSmithKline, LLC.

Low-dose radiation therapy offers substantial relief to people with painful knee osteoarthritis - American Society for Radiation Oncology (ASTRO). ASTRO. Published September 28, 2025. 

https://www.astro.org/news-and-publications/news-and-media-center/news-releases/2025/low-dose-radiation-therapy-offers-substantial-relief-to-people-with-painful-knee-osteoarthritis

Hoveidaei A, Karimi M, Salmannezhad A, Tavakoli Y, Taghavi SP, Hoveidaei AH. Low-dose Radiation Therapy (LDRT) in Managing Osteoarthritis: A Comprehensive Review. 

. 2025;102:100777. Published 2025 Feb 12. 

Low-dose Radiation Therapy | Texas Oncology. Texasoncology.com. Published 2026. Accessed April 29, 2026. 

https://www.texasoncology.com/cancer-care/low-dose-radiation-therapy

Low-dose radiation therapy is gaining attention in the US for osteoarthritis and inflammatory pain, with clinicians citing anti-inflammatory effects.

Internal Medicine

Internal Medicine condition center page, resources on the topics of medical news and expert insight into internal medicine can be found. Content includes articles, interviews, videos, podcasts, and breaking news on internal medicine research, treatment, and drug development.

Hospital Medicine

The HCPLive hospital medicine page is a comprehensive resource for clinical news and insights on the emergency medicine specialty. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for emergent care, and more.

Strategic Alliance Partnership

Baba Inusa, MBBS, is a Consultant Paediatrician in the School of Life Course & Population Sciences at King's College London.

Using SWAY’s Global Sickle Cell Data to Close Access, Treatment Gaps

Multinational data from SWAY points to an increased incidence of sickle cell in Sub-Saharan Africa despite persistent gaps in treatment access.

Senior study investigator Baba Insusa, MBBS, points clinicians toward actionable solutions, including global support for medications like hydroxyurea and penicillin, along with collaboration between sub-Saharan Africa (SSA), low- and middle-income countries (LMICs), and high-income countries (HICs), in this interview with 

The SWAY data analysis aimed to compare the impact of sickle cell disease—including symptoms, complications, and quality of life—on patients in SSA compared with those in LMICs and HICs.

The study included 2,145 patients aged 12 years and older across three regions: SSA (n = 519), LMICs (n = 422), and HICs (n = 1,204). Patients in SSA were younger overall, with a median age of 15 years, compared with 19 years in LMICs and 29 years in HICs.

“Funding is very important, but what we really need is a joined-up approach that provides a standard framework countries can use—so we can learn from each other and apply best practices across the board,” Inusa said.

Catch up with Part 1 of our conversation here!

Across regions, patients reported broadly similar symptom patterns and complications, suggesting a consistent global clinical phenotype of sickle cell disease. The most common symptoms included fatigue (34%–77%), headache (39%–58%), and bone aches (32%–58%), while complications such as fever (60%–75%), infections (37%–66%), and joint-related issues (29%–65%) were also consistently observed, reinforcing the multisystem burden of disease.

Despite this consistency, differences emerged in acute disease burden and treatment access. More than five vaso-occlusive crises (VOCs) in the prior year were reported in 30% of patients in SSA, compared with 22% in LMICs and 27% in HICs, notably within a younger SSA cohort. Treatment utilization also varied substantially, with lower opioid (26%) and over-the-counter analgesic use (30%) in SSA compared with HICs (73% and 64%, respectively), highlighting disparities in access and care delivery.

Expanding Access Through Essential Medicines

He emphasized that improving access to foundational therapies like hydroxyurea and penicillin should be a global priority, noting that positioning them as essential medicines—and securing support from major funding bodies—could reduce costs and improve both access and utilization.

He highlighted the need for more structured care systems, in which specialist centers are supported by generalist sites with the capacity to treat patients appropriately, helping expand access while maintaining quality of care.

He underscored the importance of incorporating patient perspectives into care and research, noting that symptoms like fatigue—historically underrecognized—are now being identified by patients as a major burden.

Looking Beyond Pain in Sickle Cell Disease

While pain remains central, he stressed that sickle cell disease extends beyond pain alone, pointing to organ damage and broader quality-of-life impacts as critical areas for both care and research.

Driving Investment and Global Collaboration

He concluded that improving outcomes will require stronger investment and collaboration across countries, organizations, and stakeholders, alongside continued efforts to standardize care frameworks and expand access globally.

“There is enough in this study to show we need better access, better investment, and prioritization of these treatments as essential medicines,” he concluded.

Editor’s Note: Inusa reports relevant disclosures with Novo Nordisk A/S.

Inusa B, Andemariam B, Minniti C, et al. Sickle Cell Disease Burden in Sub-Saharan Africa Compared to Other Regions: Results from the SWAY Survey. 

. Published online April 2026:100092. doi:

https://doi.org/10.1016/j.bglo.2026.100092

Inusa B. Increased Sickle Cell Pain Burden in Sub-Saharan Africa Despite Younger Patients. HCPLive. Published April 28, 2026. Accessed April 29, 2026. 

https://www.hcplive.com/view/increased-sickle-cell-pain-burden-in-sub-saharan-africa-despite-younger-patients

Inusa discusses how clinicians can close gaps in sickle cell disease care and global disparities. 

Hematology

Sickle Cell

Sickle Cell condition center page, resources on the topics of medical news and expert insight into sickle cell disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on sickle cell research, treatment, and drug development.

Using SWAY’s Global Sickle Cell Data to Close Access, Treatment Gaps 

Shashank Joshi, MD, is a consultant endocrinologist at Liavati Hospital and Joshi Clinic in Mumbai.

Joshi explains the narrow window of optimal iodine levels, highlighting the risk posed by supplements and iodized salt in tipping the scales toward health risks.

Thyroid Disorders

Navigating Iodine Deficiencies and Excesses in Thyroid Health, With Shashank Joshi, MD

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

The International Eczema Council set out to create a set of consensus-based definitions of remission, LDA, and vLDA in atopic dermatitis.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

International Eczema Council Releases Definitions of Remission, Low Disease Activity

Linda Stein Gold, MD, is a dermatologist at Henry Ford Health. 

Expert panel weighs IL‑17 vs IL‑23 biologics for psoriasis, highlighting fast onset, durability, and why switching within class may work.

Video Series

IL-17 Inhibition and Long-Term Outcomes in Psoriasis

Professor of Medicine and Renal Division Chief at the University of Pennsylvania Perelman School of Medicine

Campbell answers questions about the current research and clinical landscape of APOL1-mediated kidney disease. 

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

APOL1 Reaches Turning Point While Clinical, Equity Challenges Persist, With Kirk Campbell, MD

Comparing Biologic Classes and Durability in Psoriasis

Christopher G. Bunick, MD, PhD, is an associate professor of dermatology at Yale University School of Medicine.

This Q&A interview highlights emerging therapies for atopic dermatitis, featuring Christopher G. Bunick, MD, PhD of Yale Medicine.

Positive Signals for Bispecific and Trispecific Antibodies in Atopic Dermatitis, With Christopher Bunick, MD, PhD

Brelovitug met the primary endpoint for virologic response and ALT normalization in the phase 2b portion of the AZURE-1 trial.

New Phase 2b AZURE-1 Data Signal Progress in Chronic Hepatitis D Treatment, With Tatyana Kushner, MD

Martina J. Porter, MD, is a dermatologist at Beth Israel Deaconess Medical Center.

54-week STOP-HS safety data for the JAK1-selective inhibitor povorcitinib showed no dose-dependent safety signal and few laboratory abnormalities.

Hidradenitis Suppurativa

Hidradenitis Suppurativa condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatology research, treatment, and drug development.

Contextualizing JAK Safety With Povorcitinib in HS, With Martina Porter, MD

Endocrinology experts compare pediatric and adult growth hormone deficiency—causes, testing, MRI use, and transition care tips to improve outcomes.

Recognizing Growth Hormone Deficiency — Symptoms, Presentation, and Quality of Life

Experts compare pediatric vs adult growth hormone deficiency—causes, testing, MRI use, and why retesting matters during transition to adult care.

Latest News

Q&A: How Dermatologists Can Utilize the AAD Clinical Image Collection, With Vinod Nambudiri, MD, MBA, MPH

AZURE-1: Brelovitug Meets Key Endpoints in Hepatitis D, With Tatyana Kushner, MD

Relacorilant Reduces HbA1c in Cushing’s Despite GLP-1 Treatment, With Julie Silverstein, MD

Low-Dose Radiation Therapy Gains Traction in US, With Hirsch Sudhir Matani, MD

Using SWAY’s Global Sickle Cell Data to Close Access, Treatment Gaps